Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast

被引:31
|
作者
Perin, T
Canzonieri, V
Massarut, S
Bidoli, E
Rossi, C
Roncadin, M
Carbone, A
机构
[1] IST NAZL RICOVERO & CURA CARATTERE SCI, CTR RIFERIMENTO ONCOL AVIANO, DIV PATHOL, AVIANO, ITALY
[2] IST NAZL RICOVERO & CURA CARATTERE SCI, CTR RIFERIMENTO ONCOL AVIANO, DIV SURG ONCOL, AVIANO, ITALY
[3] IST NAZL RICOVERO & CURA CARATTERE SCI, CTR RIFERIMENTO ONCOL AVIANO, DIV EPIDEMIOL, AVIANO, ITALY
[4] IST NAZL RICOVERO & CURA CARATTERE SCI, CTR RIFERIMENTO ONCOL AVIANO, DIV RADIOTHERAPY, AVIANO, ITALY
关键词
c-erbB-2; p53; ER; PR; pS2; cath-D; CD44; MLuC5; ductal carcinoma in situ of the breast;
D O I
10.1016/0959-8049(96)00037-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to obtain prognostic clinicopathological information, 49 cases of pure ductal carcinoma in situ of the breast (DCIS), were evaluated for the immunohistochemical expression of potential predictor markers including c-erbB-2 oncogene product, p53 protein, oestrogen (ER) and progesterone (PR) receptors, oestrogen-regulated proteins pS2 and cathepsin-D (cath-D), CD44 protein and 67-kDa laminin receptor (MLuC5). Immunohistochemical findings were compared with conventional pathological parameters, clinical findings, and the clinical outcome of the patients. When markers were matched to each other, statistical analyses provided a significant positive correlation between c-erbB-2 overexpression and p53 positivity (P < 0.01) and between ER and PR (P < 0.01), ER, PR and pS2 (P < 0.01), pS2 and MLuC5 (P < 0.05). Significant negative correlations between c-erbB-2 overexpression and ER (P < 0.05), PR (P < 0.01) and pS2 (P < 0.01) positivity was also observed. Data on the relationship between marker status and pathological findings revealed a significant positive trend between c-erbB-2, p53, and increased grade values (P < 0.05) and opposite results with SR receptor expression (P < 0.01). c-erbB-2 overexpression was further significantly associated with comedotype carcinoma (P < 0.05) and distribution of disease in confluent neoplastic ducts (P < 0.01). Although no statistically significant correlation among biological markers expression, clinical findings and outcome was demonstrated, overall this study indicates that tumour cells from a subset of DCIS, which includes comedotype carcinoma, express significantly unfavourable prognostic factors. Copyright (C) 1996 Elsevier Science Ltd
引用
收藏
页码:1148 / 1155
页数:8
相关论文
共 50 条
  • [1] Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast
    Iwase H.
    Ando Y.
    Ichihara S.
    Toyoshima S.
    Nakamura T.-A.
    Karamatsu S.
    Ito Y.
    Yamashita H.
    Toyama T.
    Omoto Y.
    Fujii Y.
    Mitsuyama S.
    Kobayashi S.
    Breast Cancer, 2001, 8 (2) : 98 - 104
  • [2] Grading and Study of Biological Markers in Ductal Carcinoma in situ and Concurrent Infiltrating Ductal Carcinoma of Breast
    George, Lovely
    Pai, Muktha Ramesh
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2018, 12 (04) : EC1 - EC4
  • [3] Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast
    Provenzano, E
    Hopper, JL
    Giles, GG
    Marr, G
    Venter, DJ
    Armes, JE
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (05) : 622 - 630
  • [4] Immunohistochemical Profiling of Ductal Carcinoma In Situ of the Breast
    Brown, J.
    Gillett, C.
    Pinder, S. E.
    JOURNAL OF PATHOLOGY, 2011, 224 : S10 - S10
  • [5] Immunohistochemical categorisation of ductal carcinoma in situ of the breast
    Meijnen, P.
    Peterse, J. L.
    Antonini, N.
    Rutgers, EjTh
    van de Vijver, M. J.
    BRITISH JOURNAL OF CANCER, 2008, 98 (01) : 137 - 142
  • [6] Immunohistochemical categorisation of ductal carcinoma in situ of the breast
    P Meijnen
    J L Peterse
    N Antonini
    E J Th Rutgers
    M J van de Vijver
    British Journal of Cancer, 2008, 98 : 137 - 142
  • [7] Histologic and immunohistochemical evaluation of ductal carcinoma in situ coexisting with triple negative carcinoma of breast
    Seol, H.
    Park, I.
    HISTOPATHOLOGY, 2008, 53 : 61 - 61
  • [8] Molecular markers in ductal carcinoma in situ of the breast
    Porter, D
    Lahti-Domenici, J
    Keshaviah, A
    Bae, YK
    Argani, P
    Marks, J
    Richardson, A
    Cooper, A
    Strausberg, R
    Riggins, GJ
    Schnitt, S
    Gabrielson, E
    Gelman, R
    Polyak, K
    MOLECULAR CANCER RESEARCH, 2003, 1 (05) : 362 - 375
  • [9] Immunohistochemical evaluation of vasopressin expresion in breast fibrocystic disease and ductal carcinoma In situ (DCIS)
    William G. North
    Wendy Wells
    Michael J. Fay
    Rennie S. Mathew
    Edward M. Donnelly
    Vincent A. Memoli
    Endocrine Pathology, 2003, 14 : 257 - 262
  • [10] Immunohistochemical evaluation of vasopressin expression in breast fibrocystic disease and ductal carcinoma in situ (DCIS)
    North, WG
    Wells, W
    Fay, MJ
    Mathew, RS
    Donnelly, EM
    Memoli, VA
    ENDOCRINE PATHOLOGY, 2003, 14 (03) : 257 - 262